Cancers,
Год журнала:
2022,
Номер
14(11), С. 2641 - 2641
Опубликована: Май 26, 2022
Cholangiocarcinoma
(CCA)
represents
approximately
3%
of
gastrointestinal
malignancies
worldwide
and
constitutes
around
10–15%
all
primary
liver
cancers,
being
only
second
to
hepatocellular
carcinoma.
Mortality
from
CCA
has
been
on
the
rise
in
recent
decades,
United
States
alone
there
a
36%
increase
1999
2014,
with
over
7000
mortalities
since
2013.
Targeted
therapies,
which
have
gaining
interest
due
their
greater
specificity
toward
cancer
cells,
recently
started
FDA
approval
for
treatment
CCA.
In
this
manuscript,
we
will
go
through
timeline
current
FDA-approved
targeted
therapies
as
well
those
that
gained
breakthrough
therapy
designation.
Arthritis & Rheumatology,
Год журнала:
2023,
Номер
76(1), С. 32 - 47
Опубликована: Авг. 19, 2023
Fibroblast-like
synoviocytes
(FLSs)
contribute
to
inflammation
and
joint
damage
in
rheumatoid
arthritis
(RA).
However,
the
regulatory
mechanisms
of
FLSs
relapse
remission
RA
remain
unknown.
Identifying
FLS
heterogeneity
their
underlying
pathogenic
roles
may
lead
discovering
novel
disease-modifying
antirheumatic
drugs.
Cells,
Год журнала:
2022,
Номер
11(23), С. 3929 - 3929
Опубликована: Дек. 5, 2022
Cholangiocarcinomas
(CCAs)
are
rare
but
aggressive
tumours
with
poor
diagnosis
and
limited
treatment
options.
Molecular
targeted
therapies
became
a
promising
proposal
for
patients
after
progression
under
first-line
chemical
treatment.
In
light
of
an
escalating
prevalence
CCA,
it
is
crucial
to
fully
comprehend
its
pathophysiology,
aetiology,
possible
targets
in
therapy.
Such
knowledge
would
play
pivotal
role
searching
new
therapeutic
approaches
concerning
diseases’
symptoms
their
underlying
causes.
Growing
evidence
showed
that
fibroblast
growth
factor/fibroblast
factor
receptor
(FGF/FGFR)
pathway
dysregulation
involved
variety
processes
during
embryonic
development
homeostasis
as
well
tumorigenesis.
CCA
known
close
correlation
the
FGF/FGFR
targeting
this
axis
has
been
proposed
guidelines.
Bearing
mind
significance
molecular
different
neoplasms,
seems
most
reasonable
move
towards
intensive
research
testing
on
these
case
CCA.
However,
there
still
need
more
data
covering
topic.
Although
positive
results
many
pre-clinical
clinical
studies
discussed
review,
difficulties
lie
ahead.
Furthermore,
review
presents
up-to-date
literature
regarding
outcomes
latest
discussion
over
future
directions
FGFR-directed
Cancers,
Год журнала:
2022,
Номер
14(11), С. 2641 - 2641
Опубликована: Май 26, 2022
Cholangiocarcinoma
(CCA)
represents
approximately
3%
of
gastrointestinal
malignancies
worldwide
and
constitutes
around
10–15%
all
primary
liver
cancers,
being
only
second
to
hepatocellular
carcinoma.
Mortality
from
CCA
has
been
on
the
rise
in
recent
decades,
United
States
alone
there
a
36%
increase
1999
2014,
with
over
7000
mortalities
since
2013.
Targeted
therapies,
which
have
gaining
interest
due
their
greater
specificity
toward
cancer
cells,
recently
started
FDA
approval
for
treatment
CCA.
In
this
manuscript,
we
will
go
through
timeline
current
FDA-approved
targeted
therapies
as
well
those
that
gained
breakthrough
therapy
designation.
